Home
Market News
Breaking stock market headlines
Earnings Flash
Breaking coverage of earnings reports, forecasts & dividend updates
Trends
Market movers, trading patterns & key market indicators
Disclosures
Official filings & reports from listed Japanese companies
Explorer
Stock lists filtered by fundamental & technical metrics
Jibannet, First Half Net Income Turns to Loss, Jul-Sep Net Income Decreases by 40%
6072 Jibannet Holdings Co., Ltd. 【J-GAAP】
Earnings ReportJibannet Holdings Co., Ltd. <6072> [TSE Growth] announced its financial results after the market closed on November 13th (15:30). The consolidated net income/loss for the cumulative second quarter of the fiscal year ending March 2026 (April to September) turned into a loss of 16 million yen (compared to a profit of 6 million yen in the same period last year).
Based on the first-half performance announced by the company and the unchanged full-year plan, our calculation indicates that the consolidated net income for the October to March period (second half) is expected to significant drop 61.8% from the same period last year to 26 million yen.
In the most recent three-month period, from July to September (2Q), the consolidated net income dropped to 6 million yen, a 40.0% decrease compared to the same period last year. However, the operating profit margin remained almost flat, changing from 2.6% in the same period last year to 2.7%.
Kabutan News
Actual Results
| Fiscal Year | Revenue | Operating Profit | Ordinary Profit | Net Profit | Adj. EPS | Progress Rate vs. First Half | Announce | Accounting Standards |
|---|---|---|---|---|---|---|---|---|
| Apr - Sep, 2023 | 972 | -28 | -35 | -60 | -2.6 | ー | Nov 13, 2023 | J-GAAP |
| Apr - Sep, 2024 | 891 | 7 | 11 | 6 | 0.3 | 10.0 | Nov 13, 2024 | J-GAAP |
| Apr - Sep, 2025 | 1,538 | 6 | 4 | -16 | -0.8 | 14.3 | Nov 13, 2025 | J-GAAP |
| YoY | +72.6% | -14.3% | -63.6% | - | - |
First Half Results vs. Previous Guidance
| Fiscal Year | Revenue | Operating Profit | Ordinary Profit | Net Profit | Adj. EPS | Adj. Dividend | Announce | Accounting Standards |
|---|---|---|---|---|---|---|---|---|
| Apr - Sep, 2025 Guidance | 1,450 | -31 | -34 | -46 | -2.1 | 0 | May 14, 2025 | J-GAAP |
| Apr - Sep, 2025 Results | 1,538 | 6 | 4 | -16 | -0.8 | 0 | Nov 13, 2025 | J-GAAP |
| Revision Rate | +6.1% | - | - | +65.2% | +63.4% |
Current Period Guidance
Second Half Results
| Fiscal Year | Revenue | Operating Profit | Ordinary Profit | Net Profit | Adj. EPS | Adj. Dividend | Announce | Accounting Standards |
|---|---|---|---|---|---|---|---|---|
| Oct - Mar, 2024 | 986 | 102 | 99 | 68 | 3.0 | 0 | May 14, 2025 | J-GAAP |
| Oct - Mar, 2025 Guidance | 1,612 | 24 | 24 | 26 | 1.2 | 0 | Nov 13, 2025 | J-GAAP |
| YoY | +63.5% | -76.5% | -75.8% | -61.8% | -60.9% |
Current Period Guidance
| Fiscal Year | Revenue | Operating Profit | Ordinary Profit | Net Profit | Adj. EPS | Adj. Dividend | Announce | Accounting Standards |
|---|---|---|---|---|---|---|---|---|
| Mar, 2024 | 1,877 | -48 | -58 | -95 | -4.2 | 0 | May 14, 2024 | J-GAAP |
| Mar, 2025 | 1,877 | 109 | 110 | 74 | 3.3 | 0 | May 14, 2025 | J-GAAP |
| Mar, 2026 Guidance | 3,150 | 30 | 28 | 10 | 0.5 | 0 | May 14, 2025 | J-GAAP |
| YoY | +67.8% | -72.5% | -74.5% | -86.5% | -86.2% |
Quarterly Results
| Fiscal Year | Revenue | Operating Profit | Ordinary Profit | Net Profit | Adj. EPS | Operating Profit Margin | Announce | Accounting Standards |
|---|---|---|---|---|---|---|---|---|
| Jul - Sep, 2024 | 462 | 12 | 14 | 10 | 0.5 | 2.6 | Nov 13, 2024 | J-GAAP |
| Oct - Dec, 2024 | 471 | 1 | -5 | -8 | -0.4 | 0.2 | Feb 13, 2025 | J-GAAP |
| Jan - Mar, 2025 | 515 | 101 | 104 | 76 | 3.3 | 19.6 | May 14, 2025 | J-GAAP |
| Apr - Jun, 2025 | 725 | -16 | -15 | -22 | -1.0 | -2.2 | Aug 8, 2025 | J-GAAP |
| Jul - Sep, 2025 | 813 | 22 | 19 | 6 | 0.3 | 2.7 | Nov 13, 2025 | J-GAAP |
| YoY | +76.0% | +83.3% | +35.7% | -40.0% | -40.4% |
Related Articles
CAPITA, Ordinary Profit Forecast for the Fiscal Year Revised Downward by 6%, Dividend Revised Upward by 6 Yen
Japan Animal Referral Medical, Ordinary Profit Forecast for the Fiscal Year Revised Upward by 20%, Raises Record High Profit Forecast
Noile-Immune Biotech, The Current Fiscal Year's Undisclosed Net Income to Narrow
SPRIX, 13% Increase in Ordinary Profit for The Current Fiscal Year
ITFOR, First Half Ordinary Profit Revised Downward to an Unexpected 21%Decrease, Current Fiscal Year Dividend Revised Upward by 20 Yen
FRUTA FRUTA, First Half Ordinary Profit Increases by 3.7 times, Jul-Sep Ordinary Profit Increases by 40%
jig.jp, First Half Ordinary Profit Decreases by 3%, Jul-Sep Ordinary Profit Decreases by 11%
JAPAN INSULATION, First Half Ordinary Profit Increases by 73%, Jul-Sep Ordinary Profit Increases by 65%
BRUNO, Jul-Sep (1Q) Ordinary Profit Turns to Profit
CHANGE Holdings, First Half Net Income Decreases by 25%